Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation for immunological diseases, announced its participation in several upcoming investor conferences throughout September 2026. The company will present and participate in fireside chats at major events hosted by Wells Fargo, Citi, H.C. Wainwrig…